This page collects the key figures and concepts from this lesson. Use it as a study reference; HSCI 230, 341, and 410 will assume familiarity with this material.

Key figures introduced in this lesson

A consolidated course glossary will be published on the HSCI 130 index page.

Introduction and Overview

For most of human history, pregnancy and childbirth killed approximately one woman in 100 per delivery — and women had many more deliveries than they do now. The cumulative lifetime risk of maternal death was therefore astonishingly high. The fact that maternal mortality is no longer routine in industrialized countries is one of public health's largest achievements. The fact that it remains stubbornly inequitable — both globally and within wealthy countries — is one of its largest failures. This section traces the history. We meet Semmelweis again, this time from a maternal-mortality rather than a hand-hygiene perspective. We follow the 100-fold decline of maternal mortality in industrialized countries through the 20th century. And we examine the 21st-century US rebound — a public health failure that no other high-income country has experienced — and its sharp racial disparities.

Childbed fever and the Semmelweis story

We met Ignaz Semmelweis in Module 3 as a hand-hygiene pioneer. From a maternal-mortality lens, his story is even sharper. The Vienna General Hospital maternity service where Semmelweis worked in the 1840s operated two clinics. The First Clinic was staffed by physicians and medical students, who spent their mornings performing autopsies (often on women who had died of puerperal fever) and their afternoons delivering babies. The Second Clinic was staffed by midwives, who did no autopsies. Maternal mortality from puerperal fever — also known as childbed fever — averaged approximately 18% on the First Clinic and approximately 2% on the Second Clinic. The disparity was so large that pregnant women in Vienna would beg to be admitted to the Second Clinic. Some, faced with admission to the First, gave birth in the street instead — and had lower mortality than those admitted to the physician-staffed clinic.

Semmelweis hypothesized in 1847 that 'cadaverous particles' transferred from autopsies to delivering mothers via physicians' unwashed hands were the cause. He instituted a strict protocol requiring physicians to wash their hands with chlorinated lime water between autopsies and deliveries. Maternal mortality on the First Clinic dropped to match the Second Clinic — from 18% to below 2%. The intervention saved thousands of lives. Semmelweis was nonetheless ostracized by his medical colleagues, eventually committed to an asylum, and died there at age 47.

The Semmelweis story is taught now as a parable about resistance to evidence in medicine. From a maternal mortality lens, it is also a parable about what happens when a problem affects only women. Maternal mortality at 18% per delivery would have been treated as a national emergency if it had affected any other patient population. It was treated as background noise because the affected population was women, mostly poor, in hospitals that catered primarily to those who had no alternative. The pattern of underweighting maternal mortality as a public health priority is unfortunately not extinct, as we will see.

The 20th-century decline

Maternal mortality in industrialized countries fell roughly 100-fold between 1900 and 2000, driven by a combination of interventions. Antisepsis and aseptic technique (descendants of Lister and Semmelweis) dramatically reduced infection. Antibiotics (sulfa drugs from 1935, penicillin from 1944) made survivable the infections that did occur. Blood transfusion (made routinely safe through blood typing, which began with Karl Landsteiner's 1901 work and matured through the mid-20th century) made survivable postpartum hemorrhage that had previously been uniformly fatal. Anaesthesia made cesarean section a survivable procedure rather than a desperate last resort. Prenatal care — the systematic monitoring of pregnant women for predictable complications — emerged in the early 20th century and is now considered standard. Skilled birth attendance — having a trained professional present during delivery — became near-universal in industrialized countries by mid-century.

The pattern of decline varies by country. In the UK, maternal mortality fell from approximately 400 per 100,000 live births in 1900 to approximately 9 per 100,000 by 2000. In the US, the decline was steeper through mid-century but plateaued earlier; by 2000, US maternal mortality was approximately 8 per 100,000. Canadian maternal mortality declined on a similar trajectory to other industrialized countries, reaching approximately 6 per 100,000 by 2000. The achievement is unambiguous: a population health gain of roughly two orders of magnitude in a century. Few public health interventions can claim a comparable record.

Globally, the decline has been more uneven. Maternal mortality in some low-income countries remains above 500 per 100,000 live births — close to the historical baseline. The Millennium Development Goal target of reducing global maternal mortality by 75% between 1990 and 2015 was substantially missed. The Sustainable Development Goal target of reducing maternal mortality to below 70 per 100,000 by 2030 is also unlikely to be met globally, though many individual countries have made dramatic progress. The interventions that work are well-characterized: skilled birth attendance, emergency obstetric care, family planning, prenatal care. The political and economic conditions to deliver them at scale are the limiting constraint.

The 21st-century rebound: the US maternal mortality paradox

Beginning around 2000, the US maternal mortality rate began to rise — slowly at first, then more dramatically. By 2020, the US maternal mortality ratio had reached approximately 24 per 100,000 live births, having tripled from its mid-1990s baseline. The COVID-19 pandemic accelerated the rise; by 2021, the official US maternal mortality ratio was approximately 33 per 100,000, the highest in any high-income country. The US is the only high-income country with rising maternal mortality in the 21st century. The pattern is now described as the US maternal mortality paradox.

The reasons are debated but several contributors are consistently identified. Pre-existing chronic conditions among pregnant women have risen (obesity, hypertension, diabetes); average maternal age at first birth has risen; access to care has become more fragmented and unequal under the US health insurance system; postpartum care (the period when many maternal deaths occur) is particularly underserved in the US; and racial and structural barriers to high-quality maternity care have not been adequately addressed. Some methodological work suggests that improved death certificate coding accounts for part of the apparent rise — but only a part. The substantive rise is real.

The racial disparity is sharp. Black women in the US have approximately 3× the maternal mortality of white women (approximately 70 per 100,000 vs. approximately 27 per 100,000 in 2021). The disparity is not explained by income, education, or insurance status; controlling for these reduces but does not eliminate the gap. Educated, insured Black women have higher maternal mortality than uninsured, less-educated white women. The pattern is most often interpreted as reflecting structural and interpersonal racism in healthcare — manifested as dismissal of pain, delays in diagnosis, communication failures, and assumptions about the patient's likely behavior and adherence. Tennis player Serena Williams's near-fatal postpartum experience in 2017, which she has discussed publicly, has been pointed to as a high-profile case of how even resourced, prominent Black women can face delays in care that lower-resource Black women face routinely.

Indigenous women in Canada similarly experience approximately 2× the maternal mortality of non-Indigenous women, with similar attributions to structural racism, jurisdictional confusion about responsibility for Indigenous health care, and the legacy of colonial trauma affecting both health status and trust in the health system. The Native Women's Association of Canada has been advocating for systemic reform of maternal care for Indigenous women, with some recent progress (including the First Nations Health Authority's prenatal program in BC) but persistent gaps.

What gets fixed when something gets fixed

The contemporary policy response to maternal mortality varies by jurisdiction. Several US states have introduced maternal mortality review committees — interdisciplinary panels that review each maternal death in detail and identify preventable factors. The committees have produced findings consistent across jurisdictions: roughly 80% of US maternal deaths are deemed preventable (Petersen et al., 2019), with the major preventable causes being delayed recognition and treatment of postpartum hemorrhage, hypertensive emergencies, cardiovascular events, mental health crises, and substance use overdoses. Approximately 30% of US maternal deaths occur during the late postpartum period (between 6 weeks and 1 year after delivery), a period traditionally outside the focus of obstetric care.

Reforms that have shown promise include: extended postpartum Medicaid coverage (most states have extended coverage from 60 days to 12 months postpartum since 2021); standardized postpartum care visits with mental health and cardiovascular screening; community-based doula programs; and improved infrastructure for hospital-based emergency obstetric care (AIM bundles, hemorrhage protocols). Whether these reforms will reverse the maternal mortality trend remains to be seen.

Canadian maternal mortality has been more stable but is showing some concerning patterns. Mental health-related maternal deaths (including suicide) have risen in some jurisdictions. The opioid crisis has produced an increase in maternal deaths from drug toxicity in pregnancy and the postpartum period. Indigenous maternal mortality gaps persist. The Canadian Maternal Health Strategy, under development as of 2026, is intended to coordinate provincial and federal action on these issues. Whether it succeeds will be a substantial public health question of the late 2020s.

Introduction and Overview

Reproductive choice is a public health issue because being able to time and space pregnancies has measurable health consequences for women, children, and families. The history of how that choice became available is contested and uncomfortable. It involves a movement led by a complicated and sometimes troubling figure (Margaret Sanger), a technology developed in part for ethically dubious reasons (early Pill trials in Puerto Rico), and downstream social effects that have reshaped women's lives in industrialized countries more profoundly than perhaps any other 20th-century technology. The discussion is unavoidably political. The substantive history is also unambiguously public health.

Margaret Sanger and the birth control movement

Margaret Sanger (1879–1966) is the figure most associated with the modern birth control movement in North America. She trained as a nurse in early-20th-century New York, working with poor immigrant communities where she saw the consequences of unplanned and closely-spaced pregnancies firsthand. Her sister had died of complications from an unsafe abortion. Sanger came to view contraception as essential to women's health and freedom, and she committed her career to making it legal and accessible.

Her advocacy was not subtle. She founded the first US birth control clinic in Brooklyn in October 1916 and was arrested within nine days under the 1873 Comstock Act, which prohibited the distribution of contraceptive information or materials. She was repeatedly arrested and jailed in the following years. The organization she founded — initially the American Birth Control League (1921), later renamed Planned Parenthood Federation of America (1942) — has been one of the most consequential reproductive health organizations in US history. By the time Sanger died in 1966, contraception was legal across the United States, oral contraceptives were available, and the birth control movement had largely succeeded in its primary aim.

Sanger's legacy is contested. She made contraception a public good and her advocacy was effective. She also expressed views — particularly in the 1920s and 1930s — that aligned with the eugenics movement of the era. She wrote approvingly of differential birth rates among 'desirable' and 'undesirable' populations. She gave a 1926 speech to a women's auxiliary of the Ku Klux Klan. She supported sterilization in some circumstances. These views were not peripheral to her thinking; they were part of how she argued for birth control in some of her writing. Planned Parenthood publicly disavowed Sanger's eugenic views in 2020 and removed her name from the New York City Planned Parenthood center.

The careful contemporary reading treats both as true and distinct facts about the same person. Sanger transformed reproductive health and helped make contraception a public good — a benefit primarily to poor and working-class women. She also expressed views that were racist by contemporary standards and harmful in their implications. The complexity of the figure is real and is part of the history students should know.

The Pill and the social transformation

The first oral contraceptive, Enovid (norethynodrel + mestranol), was developed by chemists at G.D. Searle pharmaceutical company in the 1950s, building on work by Mexican chemist Carl Djerassi who had synthesized the first oral progestin compound in 1951. The clinical trials that led to FDA approval were conducted in part in Puerto Rico in 1956 — a setting chosen partly because of permissive regulation and partly because of the desire to test in non-white populations before broader release. The trials' informed-consent procedures fell far short of modern standards; several women died during the trials of complications that may or may not have been related to the drug. The decision to proceed to FDA approval despite these deaths has been criticized retrospectively.

Enovid was approved by the FDA in 1960 — initially for menstrual regulation, with contraception as an off-label use that became the rapid de facto application. By 1965, approximately 6.5 million American women were taking the Pill. By 1967, approximately 12.5 million women globally were. Diffusion in Canada and elsewhere followed quickly. The Pill became, within roughly a decade, the most widely-used contraceptive method in industrialized countries.

The social consequences were extraordinary. Claudia Goldin and Lawrence Katz, economists at Harvard, published a series of papers in the 2000s that documented the causal effects of Pill availability on women's economic and educational trajectories. Using state-by-state variation in the age at which women could legally access the Pill (which varied across US states through the late 1960s and early 1970s), Goldin and Katz showed that Pill access produced substantial increases in women's college attendance, professional school enrollment, age at first marriage, age at first birth, and labor force participation. The effects were causal — driven by the timing of legal access — and large. The Pill's effects on women's labor force participation are among the most studied causal stories in social science. Goldin received the 2023 Nobel Memorial Prize in Economic Sciences, in part for this work.

The Pill's downstream effects ramified through almost every aspect of social life. Fertility timing shifted: women began delaying first births into their late 20s and 30s, and total fertility rates declined as women gained reliable control over their reproduction. Household income shifted: women's increased earning power changed marriage markets, divorce rates, and family economics. The professions changed: medicine, law, and academia opened to women in numbers that had been politically impossible before the Pill. The intergenerational effects continue: the daughters and granddaughters of Pill-era women have had qualitatively different educational and career trajectories than would have been possible without effective contraception.

Contraception beyond the Pill

The Pill is the most-discussed contraceptive technology but it is no longer the most-used in many populations. Long-acting reversible contraceptives (LARCs) — particularly the levonorgestrel-releasing intrauterine system (Mirena, Skyla, Liletta, Kyleena) and the etonogestrel contraceptive implant (Nexplanon) — have become substantially more common since the early 2000s. LARCs have substantially higher real-world effectiveness than the Pill, with one-year failure rates of approximately 0.1-0.5% vs. approximately 7-9% for the Pill (the difference is primarily about compliance). The CHOICE Project (St. Louis, 2007-2014) demonstrated that when LARCs are offered at no cost with adequate counseling, uptake is high and unintended pregnancy rates drop dramatically (Peipert et al., 2012).

The introduction of medication abortion in the late 1980s and 1990s further expanded options. Mifepristone (RU-486) was approved in France in 1988 and the US in 2000. The combination of mifepristone and misoprostol provides safe and effective abortion through approximately 10 weeks gestation, has been further extended through telehealth and self-managed protocols, and has substantially changed both the politics and the public health profile of abortion. In Canada, mifepristone became available in 2017 and has rapidly expanded access, particularly in rural and remote communities where surgical abortion is unavailable.

The contemporary contraceptive technology landscape continues to evolve. The 2023 FDA approval of over-the-counter Opill (norgestrel, the first non-prescription oral contraceptive in the US) and the introduction of long-acting injectable contraception in various forms have expanded options. Male contraceptive options remain limited (condoms, vasectomy) despite decades of research; several novel male contraceptive candidates are in clinical trials but none has been approved.

Reproductive rights as health policy

The legal landscape around reproductive rights is a public health issue because access to safe abortion is a major determinant of maternal morbidity and mortality. In countries where abortion is broadly legal and accessible, maternal mortality from unsafe abortion is essentially eliminated. In countries where abortion is severely restricted, unsafe abortion remains a major contributor to maternal mortality — the WHO estimates approximately 39,000 deaths per year globally from unsafe abortion, with the burden concentrated in countries with the most restrictive laws (Ganatra et al., 2017).

The US Dobbs v. Jackson Women's Health Organization decision (2022) overturned the 1973 Roe v. Wade ruling that had established a federal constitutional right to abortion in the US. Following Dobbs, approximately 14 US states have severely restricted or banned abortion. The public health consequences are already documented: increased maternal morbidity in those states, departures of obstetric clinicians citing legal uncertainty, and travel by patients to states with broader access. Whether US maternal mortality will continue to rise as a consequence of Dobbs is being studied in real time.

Canada's legal framework is substantially different. The 1988 R. v. Morgentaler Supreme Court decision struck down Canada's existing abortion law, and Parliament has not subsequently enacted a replacement. Abortion is therefore not regulated as a specific procedure under criminal law in Canada; it is regulated under general medical practice frameworks. Access varies substantially by province, and rural and remote access is a persistent gap. Provincial coverage of abortion under health insurance is comprehensive in some provinces and limited in others.

The public health framing of reproductive rights is that access to safe, legal abortion is part of a comprehensive reproductive health framework that also includes contraception, prenatal care, sex education, and safe delivery. The political framing — in much of North America — treats abortion as a discrete moral question separate from this broader framework. The disjunction is consequential: countries that have approached reproductive health as integrated systems tend to have better outcomes across multiple indicators than countries that have segmented it into contested political questions.

Introduction and Overview

Sexually transmitted infections sit at the intersection of biology, behaviour, stigma, and ethics. The single most consequential case in research ethics in modern history is a US Public Health Service syphilis study that ran from 1932 to 1972 — for 25 years after the standard of care for syphilis became known and effective. Understanding the Tuskegee Syphilis Study is mandatory for any public health student. Its consequences shaped the modern research ethics framework, but it also continues to shape relationships between Black communities and medical institutions in ways that are still consequential. This section walks through the case carefully and discusses the broader history of STI control as a public health domain.

The Tuskegee Syphilis Study (1932-1972)

Beginning in 1932, the U.S. Public Health Service enrolled approximately 600 African American men in Macon County, Alabama — 399 with latent syphilis, 201 without — in a research study purportedly designed to observe the natural course of untreated syphilis. The men were poor sharecroppers, most with limited literacy. They were told they were being treated for 'bad blood,' a vague folk diagnosis. They were given free physical examinations, transportation to clinics, meals on examination days, and free burial insurance (which was the actual research mechanism for obtaining autopsies). They were not told they had syphilis. They were not told the study's purpose was observation rather than treatment.

The study continued for 40 years. In 1947, penicillin became the standard of care for syphilis treatment — a single course of injections that reliably cures the disease in nearly all cases. The Tuskegee study investigators deliberately withheld penicillin from the participants. They also worked to ensure participants would not receive treatment from other sources: when the men were drafted into WWII military service, the Public Health Service intervened to exempt them from the routine syphilis screening and treatment provided to other military personnel. As local health departments began treating syphilis cases in Alabama after WWII, the Public Health Service worked to identify Tuskegee participants and ensure they were not included.

The study was not secret. It was published in medical journals throughout its 40-year run. Hundreds of physicians and public health officials were aware of it. None intervened. The Tuskegee participants and their wives (some of whom became infected after the men were enrolled, since the men were not told to use protection) were not informed of their condition.

The study ended in November 1972, after Jean Heller of the Associated Press published an exposé based on whistleblower disclosures from Peter Buxtun, a Public Health Service investigator who had attempted internally for years to stop the study. By the time the study was terminated, dozens of the original participants had died of syphilis, many had infected their wives, and at least 19 children had been born with congenital syphilis. The US government formally apologized in 1997 when President Clinton invited surviving participants to the White House. A class-action settlement provided modest financial compensation to participants and their families.

The Belmont Report and the modern research ethics framework

The exposure of Tuskegee in 1972 produced an unprecedented regulatory and ethical response. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research was established by federal law in 1974. The Commission worked for four years on what became the 1979 Belmont Report, a foundational document of modern research ethics that articulated three core principles for research with human subjects: respect for persons (autonomy, informed consent), beneficence (maximizing benefits and minimizing harm), and justice (fair distribution of research burdens and benefits).

The Belmont Report shaped the modern Institutional Review Board (IRB) system in the US, the Research Ethics Board (REB) system in Canada, and analogous structures in most countries with substantial biomedical research enterprises. Canadian research ethics is now governed primarily by the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2), which is in its second edition (most recently updated in 2022) and applies to research funded by Canada's three federal research agencies (CIHR, NSERC, SSHRC). TCPS2 Chapter 9 specifically addresses research involving First Nations, Inuit, and Métis communities, drawing on the OCAP principles and Indigenous data sovereignty frameworks.

The modern research ethics infrastructure prevents Tuskegee-style studies from happening through several layers: (1) prior IRB/REB review of any proposed research; (2) requirements for informed consent that meet specific procedural standards; (3) ongoing monitoring of approved studies; (4) special protections for vulnerable populations (children, prisoners, people with cognitive impairments, pregnant women, others); (5) public reporting of trial results; (6) journal-level requirements that submitted research meet ethical standards. None of these layers is perfect. Cases of research ethics violations continue to occur. But the structure makes a Tuskegee-style decades-long deliberate withholding of treatment essentially impossible to execute in any country with functioning research ethics infrastructure.

Why Tuskegee still matters

Tuskegee is taught because it cannot be filed away as a historical aberration. The study was conducted by a respectable federal agency, by well-credentialed scientists at major institutions, with the knowledge of hundreds of physicians and public health officials. It continued for two decades after the treatment was discovered. The conditions that produced it — racism, paternalism, the assumption that some lives count less, institutional inertia, professional silence — were not unique to that study or that era and have not been eliminated by the post-Belmont infrastructure.

The downstream effects on Black communities' trust in medical institutions are real and consequential. Survey data has consistently shown elevated medical mistrust among Black Americans compared with white Americans. The mistrust contributes to lower rates of organ donation, lower participation in clinical trials, and lower uptake of preventive services. The COVID-19 vaccination campaign in Black communities required substantial additional outreach and partnership work specifically because of this distrust. Public health workers in 2026 still encounter the legacy of Tuskegee in their work.

Canadian research ethics has its own analogous reckonings. The Indian residential school system (operated by federal government from the 1880s through 1996) included extensive medical experimentation on Indigenous children, including malnutrition experiments documented in detail by historian Ian Mosby (2013). Forced sterilization of Indigenous women — particularly in the 1960s and 1970s — has been documented in detail and is the subject of ongoing class-action litigation (Pegoraro, 2015). The contemporary work of decolonizing Canadian health research, including the OCAP principles and TCPS2 Chapter 9, is partly a response to this history.

The general lesson is that research ethics infrastructure is necessary but not sufficient. Vigilance has to be ongoing. Contemporary examples of research ethics concerns include: research on vulnerable populations in low-income countries with weaker oversight, certain pharmaceutical industry trials with restrictive comparator arms, surveillance research on undocumented populations, and the use of administrative health data without adequate consideration of the communities the data describes. The IRB/REB system catches most problems; not all.

STIs in Canadian public health today

Contemporary STI epidemiology in Canada presents several active challenges. Chlamydia is the most-reported reportable infection in Canada, with annual case counts continuing to rise. Gonorrhea cases have risen substantially since the early 2010s, with the emergence of antibiotic-resistant strains that are increasingly difficult to treat. Syphilis, after decades of decline, has rebounded dramatically across Canada since approximately 2015; congenital syphilis (transmission from mother to baby in utero) has appeared in jurisdictions that had not seen cases in a generation. HIV transmission rates are stable but the disease persists, with particular concentrations in specific subpopulations (men who have sex with men, people who inject drugs, Indigenous communities in some regions).

The public health response combines several strategies. Pre-exposure prophylaxis (PrEP) for HIV — daily oral antiretroviral medication that prevents HIV infection in people at risk — has been available since 2012 and has substantially reduced HIV transmission in populations with adequate uptake. U=U messaging (Undetectable equals Untransmittable) has reduced stigma around HIV diagnosis and improved treatment uptake. HPV vaccination, introduced for adolescents from 2008 onward, is now driving substantial declines in cervical cancer and is increasingly being extended to males (Drolet et al., 2019). Routine STI testing in primary care and sexual health clinics has expanded.

The contemporary challenges include the antibiotic resistance trajectory for gonorrhea (the WHO has classified gonorrhea among its priority pathogens for antibiotic development), the resurgence of syphilis (which is connected to opioid crisis, housing instability, and gaps in primary care access for marginalized populations), the persistence of HIV stigma in some communities, and the slow expansion of HPV vaccination in some provinces. Comprehensive sexuality education in schools — which has well-documented effects on STI rates, teen pregnancy, and other outcomes — remains politically contested in some Canadian jurisdictions.

Introduction and Overview

HIV/AIDS is a public health event whose social history is as important as its biology. The activist response transformed clinical trial design, drug regulation, and the ethics of research with affected communities in ways that have shaped public health far beyond HIV itself. The story arc — from the first cases reported in 1981 through the catastrophic mortality of the late 1980s and early 1990s, the introduction of HAART in 1996, and the contemporary U=U framework — is the most consequential infectious disease story of the late 20th century. This section walks through it.

From 'GRID' to the identification of HIV

The first cases of what would become recognized as HIV/AIDS were reported by the U.S. CDC's Morbidity and Mortality Weekly Report on 5 June 1981 — five cases of Pneumocystis carinii pneumonia in previously healthy gay men in Los Angeles (CDC, 1981). The MMWR report was three pages and easy to overlook. It was nonetheless one of the most consequential single publications in the history of public health. Within months, similar cases were being reported across the United States and in Europe, and within a year the syndrome had been identified in hemophiliacs (suggesting blood-borne transmission), injection drug users, and infants born to infected mothers.

The early case-definition discussions were freighted with the politics of the affected populations. The syndrome was briefly labeled 'GRID' (gay-related immune deficiency) in 1982, reflecting both the demographic concentration of early cases and the assumption that the cause was somehow linked to gay male sexual behavior. The label was changed to 'AIDS' (Acquired Immunodeficiency Syndrome) in mid-1982 as broader case-finding showed the syndrome affected diverse populations. The terminology shift reflected the recognition that this was a population-wide infectious disease, not a 'gay disease' — though that framing persisted in public discourse for years afterward and contributed to political neglect.

The virus now called HIV (Human Immunodeficiency Virus) was identified in 1983-1984 by groups led by Luc Montagnier at the Pasteur Institute in Paris and Robert Gallo at the US National Cancer Institute. A long-running priority dispute between the two groups was eventually resolved by sharing credit; Montagnier received the 2008 Nobel Prize alongside Françoise Barré-Sinoussi. The identification of HIV enabled the development of diagnostic tests, which became available in 1985. Blood-supply screening (essential because hemophiliacs and transfusion recipients had been infected through blood products) was implemented from 1985 onward.

The political and social response in the first generation of the pandemic was disastrously slow. In the United States, President Reagan did not publicly speak the word 'AIDS' until 1985, four years and tens of thousands of deaths into the pandemic. Federal funding for AIDS research and treatment lagged behind the scale of the crisis. The dominant cultural narrative often blamed the affected populations for their own infections. The combination of political neglect and active stigma cost lives that an earlier, more vigorous response could have saved.

The catastrophic decade and HAART

The first generation of the HIV pandemic, from approximately 1981 to 1996, was characterized by extraordinarily high mortality and limited treatment options. Average time from HIV infection to death without treatment was approximately 10-12 years; for those who developed AIDS-defining illnesses, life expectancy was typically 1-3 years. The 1980s and early 1990s gay communities in major North American cities lost a generation of men. Hemophiliac communities lost a substantial fraction of their members. Injection drug users were dying in numbers that were often invisible to mainstream media coverage.

The first antiretroviral drug, azidothymidine (AZT, later renamed zidovudine), was approved by the FDA in March 1987 — at the time, the fastest FDA approval in history. AZT extended survival modestly but was used as monotherapy initially, which produced rapid emergence of resistant virus. Subsequent drugs (didanosine, zalcitabine, stavudine) were developed through the early 1990s, but all faced similar resistance problems when used alone. Combination therapy with two drugs improved on monotherapy but was still inadequate to durably suppress the virus.

The transformative moment came in 1996 with the introduction of highly active antiretroviral therapy (HAART) — combinations of three or more antiretroviral drugs from different classes. HAART achieved durable viral suppression in most patients and prevented the emergence of resistance through evolutionary mechanisms (the virus would have to acquire multiple resistance mutations simultaneously, which is statistically much less likely than acquiring one). The clinical effect was immediate and dramatic. People with HIV who responded to HAART went from preparing to die to planning long lives. AIDS-related deaths in industrialized countries dropped by 60-80% within three years of HAART introduction (Palella et al., 1998).

The shift from AZT monotherapy to combination therapy was driven in substantial part by activist pressure on regulatory agencies and the research establishment. The 5C study (later the 5C trial and analogous trials) that demonstrated combination superiority were designed with explicit community input. The conference culture of HIV research — large international meetings (the International AIDS Conference, the Conference on Retroviruses and Opportunistic Infections) that bring researchers, clinicians, activists, and patients together — was unprecedented at the time and has now been emulated in many other diseases.

ACT UP and the reform of clinical research

ACT UP (AIDS Coalition to Unleash Power) was founded in March 1987 in New York City, with playwright Larry Kramer as one of the convening figures. ACT UP was a direct-action activist organization whose tactics — protest, civil disobedience, public confrontation of researchers and policymakers — were initially controversial within the medical establishment and have become foundational to the modern patient-advocacy movement.

ACT UP's specific accomplishments were substantial. The organization campaigned for: faster FDA drug approval (the FDA accelerated approval pathway, used since for many oncology drugs, traces partly to ACT UP pressure); patient and community representation on research review committees (now standard in many federal research advisory structures); broader inclusion criteria for clinical trials (the early HIV trials excluded women, injection drug users, and people with hepatitis C — populations bearing substantial HIV burden); compassionate use access to investigational therapies (now codified in expanded access programs); and treatment access pricing (the lower-cost generic antiretroviral programs that have made HAART available in low-income countries were partly the consequence of ACT UP campaigns against pharmaceutical pricing).

The phrase 'Nothing about us without us', borrowed from disability rights and elevated by ACT UP into a research-ethics principle, is now standard in patient-oriented research broadly. The contemporary structure of community-based participatory research — collaborative research between academic teams and the communities being studied, with shared authority over research questions, methods, and dissemination — owes its character to the ACT UP era. CIHR's Strategy for Patient-Oriented Research (SPOR), launched in 2011, and analogous structures in the US, UK, and elsewhere all trace lineage to HIV-era community-driven research practices.

The cultural style of ACT UP — confrontational, theatrical, willing to embarrass powerful institutions publicly — has been controversial. Subsequent patient-advocacy movements in other diseases have generally adopted more cooperative approaches with established institutions. Whether this represents progress or a loss of effective leverage is debated. ACT UP itself has retrospective canonical status that obscures how genuinely radical and disruptive it was in real time. Many of the most influential figures in contemporary public health came up through ACT UP or analogous AIDS-era organizations.

U=U and contemporary HIV

The contemporary HIV landscape is transformed from the catastrophic generation. In 2008, the Swiss Federal Commission for HIV/AIDS issued the first formal statement that a person with HIV on effective antiretroviral therapy with sustained undetectable viral load does not transmit HIV sexually. The 'Swiss Statement' was initially controversial but has been confirmed by multiple large studies (PARTNER, PARTNER 2, Opposites Attract) and is now globally accepted as U=U: Undetectable equals Untransmittable.

The U=U framework has substantial public health implications beyond the transmission claim. It has reduced stigma around HIV diagnosis (a person with treated HIV is not a risk to sexual partners). It has supported treatment-as-prevention strategies (rapidly initiating treatment after diagnosis benefits the individual and reduces population-level transmission). It has reframed HIV from a condition primarily about controlling sexual behavior to a condition primarily about access to and adherence with treatment. The framing is consistent with the broader chronic-disease-management model that HIV has become.

Pre-exposure prophylaxis (PrEP) — daily oral antiretroviral medication that prevents HIV infection in people at risk — has been available since 2012 and has substantially reduced HIV transmission in populations with adequate uptake. PrEP is now also available as a long-acting injectable (cabotegravir, approved 2021) that requires administration every two months rather than daily oral medication. PrEP coverage in Canada is generally available through provincial health insurance but with substantial variation in access, particularly for marginalized populations.

The persistent HIV inequities are demographic and geographic. Globally, the HIV burden is concentrated in sub-Saharan Africa, with substantial smaller burdens in Eastern Europe/Central Asia, Southeast Asia, and the Caribbean. In Canada, HIV incidence is concentrated in specific subpopulations: men who have sex with men remain the largest affected group, with substantial transmission in some Indigenous communities and in people who inject drugs. The 'first 90' of UNAIDS's 90-90-90 strategy (90% of people with HIV diagnosed, 90% of those treated, 90% of those virally suppressed) remains the limiting factor: testing coverage in marginalized populations is incomplete, and the diagnosis-to-treatment cascade has gaps. The 2025 target of 95-95-95 will likely be missed in Canada and most countries.

Bringing It All Together

This lesson has walked you through the full arc of the topic across all four sections. As you complete this final assessment, draw on each section to consolidate what you have learned and to prepare for the lessons that build on it.

The list below distills the core ideas the rest of the course will keep coming back to. Read them as a checklist: if any feel unfamiliar, jump back into the relevant section before you take the assessment, since later lessons will assume each of them as common ground.

Data Spotlight

Forward Link

HSCI 230 returns to ethics — Tuskegee, the Belmont Report, the Tri-Council Policy Statement — as foundational to study design. HSCI 130 gives you the historical cases the ethics frameworks were built to prevent and the substantive understanding of why those frameworks matter operationally, not just procedurally.

Final Reflection

Comprehensive Knowledge Check

This 15-question assessment covers all four sections of Lesson 5. Aim for at least 12 of 15 correct. You may retry until you reach mastery.